With the publication of the results of 2013, Merck provided a forecast of expected sales, EBITDA pre one-time items and business free cash flow for the Merck Group and its divisions for 2014. Owing to business performance in the first half of 2014, Merck confirms its forecast for the full year 2014 despite anticipated negative foreign exchange effects. The latter will stem mainly from a significant drop in the value of the U.S. dollar and the Japanese yen, yet also from the Latin American currencies. Relative to the sales of the Merck Group, we therefore continue to assume negative exchange rate effects of approximately 3–4% compared to the previous year. Merck [...]
[...] certain integrins expressed on tumor and endothelial cells, two Phase II trials were recently completed. Results of a study in patients with metastatic castrate-resistant prostate cancer (PERSEUS) were presented at 2014 ASCO Meeting. No significant improvement in progression free survival was observed and development therefore will not continue in this indication. The results of the POSEIDON study, a combination of abituzumab with Erbitux® and irinotecan in KRAS wild-type mCRC, were presented at the ESMO 16th World Congress on Gastrointestinal Cancer. The primary endpoint of increased progression free survival was not met. The addition of abituzumab to Erbitux® [...]
XLS Merck Serono | Key figures € million Q2 – 2014 Q2 – 20131 Change in % Jan.–June 2014 Jan.–June 20131 Change in % 1 The previous year’s figures have been adjusted, see “The Merck Group and its divisions”. Total revenues 1,510.7 1,560.5 –3.2 2,931.8 3,042.6 –3.6 Sales 1,446.4 1,467.6 –1.4 2,821.3 2,856.3 –1.2 Operating result (EBIT) 239.7 266.4 –10.0 475.5 436.6 8.9 Margin (% of sales) 16.6 18.2 16.9 15.3 EBITDA 444.3 477.7 –7.0 872.3 886.0 –1.6 Margin (% of sales) 30.7 32.6 30.9 31.0 EBITDA pre one-time items 452.0 474.8 –4.8 890.1 912.5 –2.5 Margin (% of sales) 31.3 32.4 31.5 31.9 Business free cash flow 337.3 485.7 –30.6 [...]
[...] B segment, and Floratil®, a leading brand in the probiotic antidiarrheal segment in Brazil. As a result, the division has become significantly larger. With the transferred sales of € 265 million, divisional sales grew on a pro forma basis by 55% to € 742 million. The transfer of the two strong brands makes better use of the potential of the consumer-oriented business model of Consumer Health. In addition, it increases the division’s exposure in Emerging Markets. This is a step in the division’s journey towards having at least three leading brands and achieving a market share of at least 3% in each of its key markets. The share of Consumer Health sales [...]
[...] both increasing life expectancy and in part also to growing prosperity in this region, along with the resulting changes in lifestyle and dietary habits. Merck Serono is continuously working to improve ways to administer medicines and active ingredients. For several years, Merck Serono has been developing novel injection devices, which make injections more user-friendly and at the same time more reliable for patients than conventional or prefilled syringes. In addition, these products make it easier for medical staff to support healthcare professionals and patients to reach their treatment goals. Examples are the electromechanical injection devices easypod™ for [...]
